AMANTA HEALTHCARE IPO

AMANTA HEALTHCARE IPO

Essential IPO Details at a Glance

Amanta Healthcare, a distinguished pharmaceutical formulation manufacturer, is set to launch its Initial Public Offering (IPO) from September 1st to September 3rd, 2025. This highly anticipated public issue offers investors an opportunity to participate in the growth trajectory of a company specializing in sterile liquid formulations. With a price band set between ₹120 and ₹126 per equity share, the IPO aims to raise ₹126 crores through a fresh issue of shares.

The IPO is structured to attract a wide range of investors, with a minimum investment of ₹14,994 for a lot size of 119 shares. Successful applicants can expect the shares to be listed on the stock exchanges by September 9th, 2025, marking a significant milestone for Amanta Healthcare and its stakeholders.

Important Dates for Amanta Healthcare IPO

• Opening Date: 01 Sep 2025
• Closing Date: 03 Sep 2025
• UPI Payment Deadline: 03 Sep 2025 (5 PM)
• Allotment Announcement: 04 Sep 2025
• Refund Processing: 08 Sep 2025
• Demat Credit: 08 Sep 2025
• Stock Market Listing: 09 Sep 2025
• Mandate Validity End: 18 Sep 2025
• Anchor Investor Lock-in Release (50%): 04 Oct 2025
• Anchor Investor Lock-in Release (Remaining): 03 Dec 2025

*Dates may be revised as per official updates.

Investors keen on participating in the Amanta Healthcare IPO should take note of these critical dates. The application window is concise, lasting only three days, emphasizing the importance of timely submission. The UPI mandate deadline is particularly crucial for retail investors, ensuring their applications are processed effectively. Following the allotment announcement, successful bids will see shares credited to their Demat accounts, just prior to the official listing on the stock exchanges. Furthermore, the lock-in release dates for anchor investors provide insights into potential liquidity events for the stock in the months following the listing.

About Amanta Healthcare: A Sector Overview

Founded in 1994, Amanta Healthcare operates in the pharmaceutical formulation manufacturing sector, specializing in sterile liquid formulations. The company’s comprehensive product portfolio caters to multiple therapeutic segments, including vital areas such as fluid therapy, respiratory care, ophthalmology, diluents, and irrigation solutions. This diverse range positions Amanta Healthcare as a significant player in critical healthcare segments.

The company’s state-of-the-art manufacturing facility, strategically located in Hariyala, Kheda district, Gujarat, spans over 66,000 square meters. This expansive facility is equipped with advanced Large Volume Parenteral (LVP) and Small Volume Parenteral (SVP) lines, utilizing cutting-edge Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM) technologies. These advanced technologies underscore Amanta Healthcare’s commitment to producing high-quality, sterile products.

Amanta Healthcare adheres to stringent quality and operational standards, evidenced by its WHO-GMP (World Health Organization – Good Manufacturing Practices) compliance. Additionally, the company holds several key international certifications, including ISO 9001:2015 for quality management, ISO 13485:2016 for medical devices quality management, ISO 14001:2015 for environmental management, and ISO 45001:2018 for occupational health and safety. These certifications highlight Amanta Healthcare’s dedication to maintaining global benchmarks in safety, quality, and environmental stewardship, distinguishing it in the highly regulated pharmaceutical industry.

IPO Funding Structure and Issue Size

The Amanta Healthcare IPO is entirely a fresh issue of equity shares, aiming to raise a total of ₹126 crores. This means that all proceeds from the IPO will directly flow into the company’s coffers, rather than being used to provide an exit for existing shareholders or promoters. A fresh issue typically signals the company’s intent to invest in future growth and operational expansion. This direct injection of capital is crucial for Amanta Healthcare as it embarks on significant capacity enhancements and strategic initiatives, which are detailed in the subsequent section on capital utilization. The absence of an Offer for Sale component indicates that the primary objective of this IPO is to fuel the company’s organic and inorganic growth ambitions, reinforcing its commitment to long-term value creation.

Strategic Deployment of IPO Proceeds

The ₹126 crores raised through the IPO are earmarked for strategic investments designed to bolster Amanta Healthcare’s manufacturing capabilities and support its overall growth trajectory. The largest portion, approximately 55.5% of the total proceeds (₹70 crores), is allocated for establishing a new manufacturing line for SteriPort. This significant investment is expected to expand the company’s capacity for producing high-demand sterile liquid products, addressing growing market needs and enhancing operational efficiency.

An additional 24% (₹30.13 crores) will be directed towards setting up a new manufacturing line for Small Volume Parenteral (SVP) products. This expansion will further diversify Amanta Healthcare’s production capabilities and allow it to cater to a broader spectrum of therapeutic requirements. Both capital expenditures are critical for the company’s expansion plans, directly addressing the potential risk of delayed growth if these capacities were not enhanced.

The remaining 20.5% (₹25.87 crores) is allocated for general corporate purposes. This flexible capital can be used for various operational needs, including working capital requirements, marketing initiatives, research and development, and other strategic objectives that arise during the course of business. This balanced allocation demonstrates Amanta Healthcare’s commitment to both focused growth investments and maintaining robust day-to-day operations.

Key Strengths Fueling Growth

• **Diversified Pharmaceutical Product Portfolio:** Established in 1994, Amanta Healthcare has built a robust and diversified product offering in the pharmaceutical sector. This broad portfolio, spanning fluid therapy, respiratory care, ophthalmic solutions, and more, reduces reliance on any single product or therapeutic segment, thereby enhancing revenue stability and market resilience.
• **Advanced Sterile Liquid Manufacturing:** The company possesses state-of-the-art capabilities in sterile liquid manufacturing across a wide volume range, from LVP to SVP. Utilizing advanced ABFS and ISBM technologies, Amanta Healthcare ensures precision, efficiency, and scalability in its production processes, which is crucial for high-quality pharmaceutical output.
• **Certified Facility with Global Standards:** Amanta Healthcare operates a modern, certified manufacturing facility that adheres to stringent international quality and operational standards. Its WHO-GMP compliance and multiple ISO certifications (9001:2015, 13485:2016, 14001:2015, 45001:2018) underscore its commitment to product quality, patient safety, and environmental responsibility, building trust among customers and regulatory bodies.
• **Extensive Domestic and Global Reach:** The company benefits from a well-established and extensive distribution and sales network, both within India and internationally. This wide reach enables Amanta Healthcare to effectively penetrate various markets, ensuring its products are accessible to a broad customer base and supporting its revenue growth.
• **Experienced Leadership and Skilled Workforce:** Amanta Healthcare is led by an experienced management team complemented by a skilled and qualified employee base. This combination of seasoned leadership and a proficient workforce fosters innovation, operational excellence, and a deep understanding of the pharmaceutical landscape, which are vital for sustained growth and navigating industry challenges.

Identifying Potential Investment Risks

• **High Customer Concentration:** Amanta Healthcare faces a notable risk due to its high customer concentration. A significant portion of its revenue may be derived from a limited number of clients, which could pose risks to revenue stability and increase dependency. The loss of a major customer or a reduction in their orders could materially and adversely impact the company’s financial performance.
• **Delay in Expansion Plans:** The company’s growth strategy heavily relies on the successful and timely setup of new manufacturing lines for SteriPort and SVP products. Any unforeseen delays in capital expenditure, regulatory approvals, or execution of these expansion projects could hinder its growth plans, impacting projected revenues and market share.
• **Promoter Guarantees Tied to Loans:** Promoter guarantees linked to the company’s loans represent a potential financial vulnerability. In the event of the company facing financial difficulties, these personal guarantees could be invoked, creating financial obligations for the promoters and potentially affecting the company’s operations and reputation.
• **Product Liability Exposure:** Operating in the sterile liquid pharmaceutical sector, Amanta Healthcare is exposed to serious product liability risks. Any defects, contamination, or adverse effects associated with its products could lead to significant legal claims, reputational damage, and financial penalties, which could severely impact its business.
• **Unsecured Borrowings and Personal Guarantees:** The presence of unsecured borrowings and additional personal guarantees in the company’s financial structure increases its financial vulnerability. While these may offer flexibility, they can also expose the company to higher interest rates or more stringent repayment terms, and in adverse scenarios, the personal assets of promoters could be at risk.

Subscription Performance and Investor Interest

Subscription statistics based on the latest available information as of 5:00 PM on September 03, 2025, indicate robust investor interest across all categories:

*GMP figures are unofficial and may vary; exchange data is more reliable.

The Amanta Healthcare IPO witnessed strong participation across all investor categories, culminating in an impressive overall subscription of 82.60 times. This high level of oversubscription reflects significant investor confidence and demand for the company’s shares. Non-Institutional Investors (NIIs) led the charge with an overwhelming subscription of 209.40 times, indicating substantial interest from high-net-worth individuals and corporate bodies. Retail Individual Investors (RIIs) also showed enthusiastic participation, subscribing 54.96 times their reserved portion, underscoring broad-based investor appetite for the IPO.

Qualified Institutional Buyers (QIBs), typically long-term institutional investors, demonstrated solid interest with a subscription of 35.86 times. The strong subscription numbers across the board are often viewed as a positive indicator for the potential listing performance and market reception of the shares. While unofficial Grey Market Premium (GMP) figures might circulate, investors are advised to rely on official exchange subscription data for a more accurate assessment of market sentiment and demand.

Participating in the Amanta Healthcare IPO

Investors can participate in this IPO via the official Dhan Kirti IPO platform before the subscription closes on September 3rd, 2025. Ensure you have a valid Demat account and a sufficient balance for your application. Review the prospectus thoroughly and consider your investment objectives and risk tolerance before applying.